Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Interest ReceivablesChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Cash from Operations: 2024-2025

  • Abivax's Cash from Operations rose 30.50% to -$37.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$164.8 million, marking a year-over-year change of. This contributed to the annual value of -$164.6 million for FY2024, which is 57.54% down from last year.
  • As of Q2 2025, Abivax's Cash from Operations stood at -$37.7 million, which was down 7.81% from -$35.0 million recorded in Q1 2025.
  • Abivax's 5-year Cash from Operations high stood at -$35.0 million for Q1 2025, and its period low was -$54.3 million during Q2 2024.
  • In the last 2 years, Abivax's Cash from Operations had a median value of -$37.7 million in 2024 and averaged -$41.2 million.
  • Data for Abivax's Cash from Operations shows a peak YoY soared of 30.50% (in 2025) over the last 5 years.
  • Over the past 2 years, Abivax's Cash from Operations (Quarterly) stood at -$54.3 million in 2024, then surged by 30.50% to -$37.7 million in 2025.
  • Its Cash from Operations was -$37.7 million in Q2 2025, compared to -$35.0 million in Q1 2025 and -$54.3 million in Q2 2024.